MANIPALHOS

- Q1 FY27 Consolidated Revenue of ₹3,091 crores, marking over 38% YoY growth. - Network EBITDA for Q1 FY27 was ₹749 crores, growing over 26% YoY (over 30% excluding a one-off gain last year). - Ex-Sahyadri Operating Margin at 25%, and network-level margin (including Sahyadri) at 24.2%. - Sahyadri Hospitals reported Q1 revenue of ₹332 crores (▲13% YoY) and EBITDA of ₹58 crores (▲19% YoY), with EBITDA margin improving to 17.5%. - Inpatient volumes grew by 39% and Outpatient volumes by 26% YoY. Average occupancy increased by 290 bps to 65%. - Commissioned 103 new beds at Nashik and launched 50th hospital (300 beds) in Electronic City, Bangalore. - Acquired Kinder Hospital in Whitefield, Bangalore, adding 100 beds; to be remodeled into a multispecialty facility. - Capex guidance: ₹4,000 crores over next 3-4 years for 3,000 new beds; ~₹2,000 crores for FY27, with ₹900 crores already spent in Q1. - Net debt to EBITDA expected to reduce from 2.8x to 0.9x in Q2 FY27 post IPO fund-led debt repayment. - Management expresses confidence in sustainable volume and complexity-led growth, driven by greenfield ramp-ups and operational efficiencies.

- The audio recording of the earnings call with analysts/investors held on August 21, 2026, at 11:00 AM is now available. - The recording has been uploaded on the company's website.

- Q1 FY27 Standalone Revenue ₹1,048.30Cr vs ₹818.02Cr (▲28.15% YoY) - Standalone EBITDA ₹290.92Cr vs ₹257.65Cr (▲12.91% YoY) - Standalone PAT ₹115.53Cr vs ₹125.93Cr (▼8.26% YoY) - Standalone EBITDA Margin 27.75% vs 31.50% (▼375bps)

- Q1 FY27 Consolidated Revenue ₹3,091Cr vs ₹2,238Cr (▲38.1% YoY) - EBITDA ₹749Cr vs ₹578Cr (adjusted, ▲29.7% YoY) - PAT ₹332Cr (adjusted, ▲30.9% YoY) - EBITDA Margin 24.2% vs 26.5% (▼230bps)

- Q1 FY27 Consolidated Revenue ₹3,091 Cr vs ₹2,238 Cr (▲38.1% YoY) - EBITDA ₹749 Cr vs ₹593 Cr (▲26.4% YoY) - PAT ₹243 Cr vs ₹254 Cr (▼4.2% YoY); adjusted PAT ₹332 Cr (▲30.9% YoY, excluding post-tax interest on Sahyadri acquisition NCD) - EBITDA Margin 24.2% vs 26.5% (▼230bps)

- Q1 FY27 Standalone Revenue from Operations ₹1,048.30 Cr vs ₹818.02 Cr (▲28.15% YoY) - Standalone EBITDA ₹250.05 Cr vs ₹223.13 Cr (▲12.06% YoY) - Standalone PAT ₹115.53 Cr vs ₹125.93 Cr (▼8.26% YoY) - Standalone EBITDA Margin 23.85% vs 27.28% (▼343bps)

- Q1 FY27 Consolidated Revenue ₹3,090.63Cr vs ₹2,237.63Cr (▲38.12% YoY) - EBITDA ₹811.17Cr vs ₹634.83Cr (▲27.77% YoY) - PAT ₹243.43Cr vs ₹254.04Cr (▼4.17% YoY) - EBITDA Margin 26.24% vs 28.37% (▼213bps) - Board approved the appointment of M/s. Price Waterhouse Chartered Accountants LLP as Statutory Auditors for a term of 5 years. - Re-appointment of Dr. Hebri Sudarshan Ballal and Mr. Puneet Bhatia as Non-Executive Directors was approved. - The Company's Articles of Association were amended to allow Temasek Group and MGHS Group to nominate directors and Executive Committee members, subject to shareholding thresholds. - The 16th Annual General Meeting (AGM) is scheduled for Tuesday, September 29, 2026, at 11:00 a.m. (IST) via video conferencing.

- Order Win: Manipal Health Enterprises to acquire Kinder Women's Hospital in Bengaluru - Order Value: ₹130 Cr. - Completion Timeline: Expected within 90 days, subject to necessary statutory and customary approvals. - Impact: Adds 100 beds, expanding Manipal's pan-India capacity to over 13,500 licensed beds and strengthening its presence in Bengaluru's Whitefield micro-market.

- Manipal Health Enterprises Limited has signed a Business Transfer Agreement to acquire the entire operations and assets of Kinder Women's Hospital and Fertility Centre ('Kinder Hospital') in Bengaluru, Karnataka. - The acquisition cost is ₹130 Crores for asset acquisition. - Kinder Hospital reported revenue of ₹20.75 Crores as of March 31, 2026, and has a current capacity of 100 beds. - The acquisition is allied to the current business and is expected to be completed within 90 days, subject to customary approvals.

- Concall Schedule - Concall Date: August 21, 2026 - Concall Time: 11:00 am (IST)

- The Board of Directors authorized Key Managerial Personnel (KMPs) to determine the materiality of events/information and make disclosures to stock exchanges under SEBI Regulation 30(5). - Authorized KMPs include the MD & CEO, CFO, COO, and Company Secretary & Compliance Officer.

New Filing detected. See link for details.

- Manipal Health Enterprises Limited has adopted a "Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information" (UPSI). - This is pursuant to Regulation 8(1) and (2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. - The code aims to ensure uniform, transparent, and fair disclosure of UPSI to prevent insider trading.

- The trading window for dealing in Manipal Health Enterprises Limited securities will close from August 05, 2026. - It will re-open 48 hours after the announcement of financial results for the quarter ended June 30, 2026. - This is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.